A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 5, 2008, Pages 328-339

  Shibata, Yoshihiro ^a   Takahashi, Hiroyuki ^a   Chiba, Masato ^a   Ishii, Yasuyuki ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Availability; Clearance; CYP2D6; CYP3A4; Desipramine; Drug drug interaction; Human hepatocytes; Indinavir; Ketoconazole; Quinidine; Serum incubation method; Terfenadine

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; INDINAVIR; KETOCONAZOLE; QUINIDINE; TERFENADINE; CYTOCHROME P450; DRUG;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER CLEARANCE; MATHEMATICAL COMPUTING; MAXIMUM PLASMA CONCENTRATION; PREDICTION; SERUM; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; COMPARATIVE STUDY; CRYOPRESERVATION; DRUG INTERACTION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PHARMACEUTICS; PREDICTION AND FORECASTING;

AREA UNDER CURVE; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; DESIPRAMINE; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; INDINAVIR; KETOCONAZOLE; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; QUINIDINE; TECHNOLOGY, PHARMACEUTICAL; TERFENADINE;

EID: 58149299889     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.328     Document Type: Article

References (48)

1. Lin, J. H.: Sense and nonsense in the prediction of drug-drug interactions. Curr. Drug Metab., 1: 305-331 (2000).
2. Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., Kumar, G., McLeod, J., Obach, S. R., Roberts, S., Roe, A., Shah, A., Snikeris, F., Sullivan, J. T., Tweedie, D., Vega, J. M., Walsh, J. and Wrighton, S.A.: The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufactures of America (PhRMA) perspective. Drug Metab. Dispos., 31: 815-832 (2003).
3. Venkatakrishnan, K., von Moltke, L. L., Obach, R. S. and Greenblatt, D. J.: Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr. Drug Metab., 4: 423-459 (2003).
4. Blanchard, N., Richert, L., Coassolo, P. and Lave, T.: Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr. Drug Metab., 5: 147-156 (2004).
5. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Duan, S. X., Wright, C. E., Harmatz, J. S. and Shader, R. I.: Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol., 36: 783-791 (1996).
6. Gibbs, M. A., Kunze, K. L., Howald, W. N. and Thummel, K. E.: Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab. Dispos., 27: 596-9 (1999).
7. Tran, T. H., von Moltke, L. L., Venkatakrishnan, K., Granda, B. W., Gibbs, M. A., Obach, R. S., Harmatz, J. S. and Greenblatt, D. J.: Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab. Dispos., 30: 1441-1445 (2002).
8. Sugita, O., Sawada, Y., Sugiyama, Y., Iga, T. and Hanano, M.: Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. A study of tolbutamide-sulfonamide interaction in rats. Biochem. Pharmacol., 30: 3347-3354 (1981).
9. Ervine, C. M., Matthew, D. E., Brennan, B. and Houston, J. B.: Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Metab. Dispos., 24: 211-215 (1996).
10. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Harmatz, J. S. and Shader, R. I.: In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol., 34: 1222-1227 (1994).
11. Tran, A., Rey, E., Pons, G., Rousseau, M., d'Athis, P., Olive, G., Mather, G. G., Bishop, F. E.,Wurden, C. J., Labroo, R., Trager, W. F., Kunze, K. L., Thummel, K. E., Vincent, J. C., Gillardin, J. M., Lepage, F. and Levy, R. H.: Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin. Pharmacol. Ther., 62: 490-504 (1997).
12. Hsu, A., Granneman, G. R., Cao, G., Carothers, L., el-Shourbagy, T., Baroldi, P., Erdman, K., Brown, F., Sun, E. and Leonard, J. M.: Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin. Pharmacol. Ther., 63: 453-464 (1998).
13. Takedomi, S., Matsuo, H., Yamano, K., Yamamoto, K., Iga, T. and Sawada, Y.: Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug Metab. Dispos., 26: 318-323 (1998).
14. Takedomi, S., Matsuo, H., Yamano, K., Ohtani, H. and Sawada, Y.: In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. J. Pharm. Pharmacol., 53: 643-651 (2001).
15. Yamano, K., Yamamoto, K., Kotaki, H., Takedomi, S., Matsuo, H., Sawada, Y. and Iga, T.: Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J. Pharmacol. Exp. Ther., 292: 1118-1126 (2000).
16. Yamano, K., Yamamoto, K., Katashima, M., Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y. and Iga, T.: Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab. Dispos., 29: 443-452 (2001).
17. Li, A. P., Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E. and Silber, P. M.: Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact., 121: 17-35 (1999).
18. Shibata, Y., Takahashi, H. and Ishii, Y.: A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos., 28: 1518-1523 (2000).
19. Shibata, Y., Takahashi, H., Chiba, M. and Ishii, Y.: Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab. Dispos., 30: 892-896 (2002).
20. Honig, P. K., Wortham, D. C., Zamani, K., Conner, D. P., Mullin, J. C. and Cantilena, L. R.: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 269: 1513-1518 (1993).
21. Woolf, E., Haddix, H. M. and Matuszewski, B.: Determination of an in vivo metabolite of a human immunodeficiency virus protease-inhibitor in human plasma by high-performance liquid chromatography with tandem mass spectrometry. J. Chromatogr. A, 762: 311-319 (1997).
22. Brøsen, K. and Gram, L. F.: Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur. J. Clin. Pharmacol., 37: 155-160 (1989).
23. Spina, E., Avenoso, A., Campo, G.M., Scordo, M. G., Caputi, A. P. and Perucca, E.: Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br. J. Clin. Pharmacol., 43: 315-318 (1997).
24. Garteiz, D. A., Hook, R. H.,Walker, B. J. and Okerholm, R. A.: Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung, 32: 1185-1190 (1982).
25. Yeh, K. C., Deutsch, P. J., Haddix, H., Hesney, M., Hoagland, V., Ju, W. D., Justice, S. J., Osborne, B., Sterrett, A.T., Stone, J.A., Woolf, E. and Waldman, S.: Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother., 42: 332-338 (1998).
26. Ciraulo, D. A., Barnhill, J. G. and Jaffe, J. H.: Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin. Pharmacol. Ther., 43: 509-18 (1988).
27. Brass, C., Galgiani, J. N., Blaschke, T. F., Defelice, R., O'Reilly, R. A. and Stevens, D. A.: Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob. Agents Chemother., 21: 151-158 (1982).
28. Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y. and Sugiyama, Y.: Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol., 38: 461-499 (1998).
29. Guentert, T. W., Holford, N. H., Coates, P. E., Upton, R. A. and Riegelman, S.: Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J. Pharmacokinet. Biopharm., 7: 315-30 (1979).
30. Okerholm, R. A., Weiner, D. L., Hook, R. H.,Walker, B. J., Leeson, G. A., Biedenbach, S. A., Cawein, M. J., Dusebout, T. D., Wright, G. J., Myers, M., Schindler, V. and Cook, C. E.: Bioavailability of terfenadine in man. Biopharm. Drug Dispos., 2: 185-190 (1981).
31. Balani, S. K., Woolf, E. J., Hoagland, V. L., Sturgill, M. G., Deutsch, P. J., Yeh, K. C. and Lin, J. H.: Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos., 24: 1389-1394 (1996).
32. Yeh, K. C., Stone, J. A., Carides, A. D., Rolan, P., Woolf, E. and Ju, W. D.: Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. J. Pharm. Sci., 88: 568-573 (1999).
33. Davies, B. and Morris, T.: Physiological parameters in laboratory animals and humans. Pharm. Res., 10: 1093-1095 (1993).
34. Lin, J. H., Chiba, M., Balani, S. K., Chen, I.-W., Kwei, G. Y., Vastag, K. J. and Nishime, J. A.: Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos., 24: 1111-1120 (1996).
35. Obach, R. S.: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 27: 1350-1359 (1999).
36. Roberts, M. S. and Rowland, M.: Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J. Pharm. Pharmacol., 38: 177-181 (1986).
37. Yun, C. H., Okerholm, R. A. and Guengerich, F. P.: Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos., 21: 403-409 (1993).
38. Zhang, W., Ramamoorthy, Y., Kilicarslan, T., Nolte, H., Tyndale, R. F. and Sellers, E. M.: Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos., 30: 314-318 (2002).
39. Venkatakrishnan, K., von Moltke, L. L. and Greenblatt, D. J.: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet., 38: 111-180 (2000).
40. Boxenbaum, H.: Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J. Pharm. Pharm. Sci., 2: 47-52 (1999).
41. Daneshmend, T. K., Warnock, D. W., Ene, M. D., Johnson, E. M., Potten, M. R., Richardson, M. D. and Williamson, P.J.: Influence of food on the pharmacokinetics of ketoconazole. Antimicrob. Agents Chemother., 25: 1-3 (1984).
42. Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K. and Lin, J. H.: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos., 24: 307-314 (1996).
43. Lin, J. H.: Human immunodeficiency virus protease inhibitors From drug design to clinical studies. Adv. Drug Deliv. Rev., 27: 215-233 (1997).
44. Spina, E., Birgersson, C., von Bahr, C., Ericsson, O., Mellstrom, B., Steiner, E. and Sjoqvist, F.: Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin. Pharmacol. Ther., 36: 677-682 (1984).
45. von Bahr, C., Spina, E., Birgersson, C., Ericsson, O., Goransson, M., Henthorn, T. and Sjoqvist, F.: Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol., 34: 2501-2505 (1985).
46. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Daily, J. P., Harmatz, J. S. and Shader, R. I.: Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J. Pharm. Sci., 87: 1184-1189 (1998).
47. Steiner, E., Dumont, E., Spina, E. and Dahlqvist, R.: Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther., 43: 577-581 (1988).
48. Spina, E., Steiner, E., Dumont, E. and Dahlqvist, R.: Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators. Psychopharmacol. Ser., 7: 201-205 (1989).